Address: Quintiles GesmbH, Leningradskiy prospekt 37A, bldg. 14, floor 4, 125167 Moscow, Office complex ARCUS,Russia
Tel: + 7 495 721 1964
Web: http://www.quintiles.com/locations/europe/Russia/
• Quintiles started operations in Russia in 1996
• First office opened in Moscow in 1997;
• Office in St. Petersburg opened in 2005;
• Office in Novosibirsk, centre of Siberian region of Russia, opened in 2007.
• 226 professional employees in total (119 in Moscow, 89 in St. Petersburg, 18 in Novosibirsk);
• Russia has centralized medical care system, common standards across the country, qualified and experienced investigators;
• 93% of staff has an university degree. Within clinical staff 56% of employees have MD degree;
• Quintiles Russia provides wide range of services including site ID and feasibility, SSU together with RA, clinical monitoring, GFR, PCC. Starting from 2010 we began our expansion in commercialization;
• Quintiles has well established relationship with regulatory bodies and also key opinion leaders across the country – which allows representation in all regions of Russia and Quintiles appears to be the leading CRO in Russia, based on the number of initial trial submissions during the year.
• Key drivers of clinical trial market in the country – governmental focus on innovative technologies including pharmaceutical industry, continued growth and further high potential of clinical research market in Russia
• Key advantages – strong and long-term Quintiles experience on country level, common medical standards and practices across the country, direct access to a network of high professional sites and investigators, high recruitment potential in wide range of indications including naïve patients, centralized submission/approval process
• Clinical services
• Commercial services
• Consulting
• Capital (investment)
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
Valenta was established in 1997 as Otechestvennye Lekarstva, and today represents the consolidation of several facilities and business holding groups. Can you give our readers an overview of the company’s…
Since 2006, Russia has witnessed quite a dynamic few years, with sweeping legislative reforms like the Law on Circulation of Medicines and development strategies like Pharma 2020. What have been…
Baker & McKenzie differentiates itself from competitors by offering an industry-focused practice. Has this model continued to give this company a leading edge in Russia, and, overall, what is your…
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Ferring is a specialty biopharmaceutical company that operates in four strategic therapeutic areas. Globally, many pharma companies have been diversifying their portfolio, and entering the OTC segment, generics segment, medical…
Lundbeck is a niche player exclusively focused on the treatment of CNS and mental health disorders. How developed do you find this niche to be in Russia? The size of…
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
The AEB works through a number of channels to promote the interests of European corporations with operations in Russia. It has a long history in this country, dating back to…
Novo Nordisk announced last year the development of an insulin plant in the Kaluga region not far from Moscow. What is the strategic significance of this plant, both for the…
Many expat managers have used Russia as a stepping-stone, but you have headed this business for an astounding 9 years. What is it about this country and about Reckitt Benckiser’s…
See our Cookie Privacy Policy Here
